Dr. Chris Roberts serves as Board Member at Clarity Pharmaceuticals. He is also an angel investor. Dr Roberts has over 40 years' experience in the medical innovation space and has served on the boards of a number of ASX listed companies. He was Chief Executive Officer of Cochlear Limited (ASX: COH) for over 11 years and was Chairman of Sirtex Medical Ltd (ASX: SRX) from 2000 to 2002 including during its listing on the ASX. Dr Roberts was also Executive Vice-President of ResMed Inc (NYSE: RMD, ASX: RMD), a global sleep disorder treatment company, from 1992 to 2004. He is currently a Non-Executive Director of ResMed Inc. and Oncosil Ltd (ASX:OSL). Dr Roberts is also actively involved in the non-commercial sector, sitting on the boards of such research institutions and government entities as Innovation Science Australia, Jobs for NSW, University of Technology Sydney Vice-Chancellor's Industry Advisory Board, the University of New South Wales Faculty of Medicine Advisory Council, Monash University Industry Council of Advisors and the NHMRC's Health Innovation Advisory Committee. Dr Roberts is a member of the Board of Governors of the Centenary Institute of Cancer Medicine and Cell Biology, and is an Honorary Fellow of the Australian Institute of Business and Economics at the University of Queensland. Dr Roberts is a PLuS Alliance Professor in biomedical engineering, an alliance of 3 universities: University of NSW, King's College London, and Arizona State University. Dr Roberts holds a BE (Honours) in Chemical Engineering from the University of New South Wales, an MBA from Macquarie University and a PhD from the University of New South Wales. He was awarded Honorary Doctor of Science degrees from Macquarie University and the University of New South Wales. He is a Fellow of the Academy of Technological Sciences and Engineering (FTSE), Fellow of the Australian Institute of Company Directors (FAICD) and Honorary Fellow of The Institution of Engineers Australia (FIEAust).